COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C) Risk / World Health Organization (WHO) (REPI)

Association Clinique Thérapeutique Infantile du val de Marne

Status: Completed

Conditions: MIS-C; Sars-CoV-2 Infection

Study type: Observational

Funder types: Other

Identifiers

NCT06255860

REPI

Details and patient eligibility

About

This study is a multicenter, international, non interventional, retrospective study about SARS-CoV-2 and Multisystem Inflammatory Syndrome (MIS-C) reinfection risk in children.

Full description

This study is based to data collection of cases (patients with MIS-C) compare to controls (patients with SARS-CoV-2 infection) occurring between 01 sep 2021 and 30 apr 2022. For this study cases and controls group will be matched for analyses.

The main of this study is to evaluate the difference of risk of occurrence of MIS-C between a first SARS-CoV-2 infection and a reinfection with SARS-CoV-2.

Enrollment: 204 patients

Sex: All

Ages: 1 day to 18 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

group 1: cases

• Patients with MIS-C (following SARS CoV-2 infection)
• Hospitalised between the 01 sep 2021 and 30 apr 2022
• Under 18 years of age
• Not vaccinated for SARS-CoV-2

group 2: controls

• Patients not hospitalised, treated by outpatient care
• With documented SARS-CoV-2 infection between the 01 sep 2021 and 30 apr 2022
• Matched with a case on age (+/- 6 months), gender and country
• Not vaccinated for SARS-CoV-2

Exclusion criteria

• Refusal to participate by patient relative or legal representative

Trial design

204 participants in 2 patient groups

children with MIS-C

Description:

hospitalized children with MIS-C

SARS-CoV-2 infection

Description:

non hospitalized children infected with SARS-CoV-2 treated by outpatient care